The present invention discloses an application of SYK serving as a therapeutic target for hepatic fibrosis/hepatic cirrhosis. Through experiments, the investor has found that a SYK gene has a higher expression during the process of hepatic fibrosis/hepatic cirrhosis, and the progression of hepatic fibrosis is accelerated by promoting activation of the hepatic stellate cells (HSCs)； and the progression of hepatic fibrosis/hepatic cirrhosis can be effectively slowed down by using a SYK inhibitor or by interfering with SYK gene expression, both of which have good therapeutic effects.
